Thu. 2 May 2024, 8:03am ET
Benzinga
News, Guidance
2024 Financial Guidance
Full year 2024 financial guidance is reiterated as follows:
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 | $1,400 million - $1,500 million | |
Net Product Revenue Growth vs. 2023 at reported FX rates1 | 13% to 21% | |
Net Product Revenue Growth vs. 2023 at CER* | 13% to 21% | |
Net revenues from collaborations and royalties | $325 million - $425 million | |
GAAP R&D and SG&A expenses | $1,900 million - $2,050 million | |
Non-GAAP R&D and SG&A expenses2 | $1,675 million - $1,775 million | |
1 Uses January 31, 2024 FX rates including: 1 EUR = 1.08 USD and 1 USD = 147 JPY | ||
2 Primarily excludes $225 - $275 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses | ||
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2023. CER is a Non-GAAP measure. |